Why the study?
Do single-dose clinical pharmacological models accurately predict the therapeutic dose range of olmesartan medoxomil in hypertensive patients?
Do single-dose clinical pharmacological models accurately predict the therapeutic dose range of olmesartan medoxomil in hypertensive patients?
Single-dose clinical pharmacology models accurately predict the effective therapeutic dose range of AT1-receptor antagonists like olmesartan, though large-scale confirmatory testing remains necessary.
Answers are grounded in this paper and cite their sources.
Volunteer pressor inhibition accurately predicted olmesartan range; extends support for early models but leaves confirmation to randomized trials.
Clinical pharmacological models Antihypertensive drugs affecting the renin-angiotensin system (RAS) can be evaluated in single-dose studies in healthy volunteers challenged with angiotensin I or II, or in subjects in whom the RAS has been activated by salt depletion. Such pharmacological studies can be used to investigate dose-response relationships. Objective The relevance of these models in predicting therapeutic dose range has been evaluated by comparing the results of pharmacological studies with those of a conventional dose-finding study in hypertensive patients with the new AT1-receptor antagonist olmesartan medoxomil. Results In healthy volunteers, 2.5-40 mg olmesartan medoxomil single doses significantly inhibited the pressor response to exogenous angiotensin I. A dose-response relationship was observed, with relevant (> 75%) inhibition occurring at doses of 10 mg and above. In a single-dose crossover study in patients with mild-to-moderate hypertension receiving a sodium-restricted diet, statistically significant lowering of mean 24-h blood pressure, measured by ambulatory blood pressure monitoring, was observed at doses of 10-80 mg. By comparison, a large-scale (n = 792), placebo-controlled, dose-ranging study in patients with mild-to-moderate hypertension likewise showed significant superiority over placebo for 10-80 mg olmesartan medoxomil once-daily doses. Conclusion Single-dose clinical pharmacology studies provided an accurate indication of the effective dose range of a new AT1-receptor antagonist Such models can be useful in identifying, for more detailed study, the likely therapeutic dose range of new drugs acting on the RAS. However, the dose-response still requires testing in large target populations.
No takes yet. Share an insight, caveat, or question.
Brunner et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: